Literature DB >> 1352440

Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.

C Charpin1, P Bonnier, A Khouzami, H Vacheret, L Andrac, M N Lavaut, C Allasia, L Piana.   

Abstract

Immunocytochemical assays were performed on frozen sections of inflammatory breast carcinomas (n = 22) using the following monoclonal antibodies (MoAb): anti-pHER2/neu, cathepsin, pS2, ER, PR and MoAb Ki67. The distribution of these proteins, known as prognostic indicators, was evaluated with an image analysis system (SAMBA, Alcatel TITN, France). On standard HE stained paraffin sections, only about 50% of inflammatory breast tumors exhibited intradermal tumor cell emboli. All tumors were strongly pHER/2neu positive. All tumors also, but to a lesser degree, were cathepsin and ki67 positive. Conversely, less than 40% were faintly ER, PR and pS2 immunoreactive. The results correlated with the high degree of malignancy of inflammatory breast carcinomas. Therefore the immuno-detection of these markers in addition to standard histological techniques appears to be a useful tool to evaluate the degree of malignancy of breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352440

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.

Authors:  S Dawood; S D Merajver; P Viens; P B Vermeulen; S M Swain; T A Buchholz; L Y Dirix; P H Levine; A Lucci; S Krishnamurthy; F M Robertson; W A Woodward; W T Yang; N T Ueno; M Cristofanilli
Journal:  Ann Oncol       Date:  2010-07-05       Impact factor: 32.976

Review 2.  Inflammatory breast cancer: no longer an absolute contraindication for breast conservation surgery following good response to neoadjuvant therapy.

Authors:  Monika Brzezinska; J Michael Dixon
Journal:  Gland Surg       Date:  2018-12

Review 3.  Matrix-degrading proteases in hormone-dependent breast cancer.

Authors:  R B Dickson; Y E Shi; M D Johnson
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells.

Authors:  A E O'Donoghue; D N Poller; J A Bell; M H Galea; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

Review 5.  Making Connections: p53 and the Cathepsin Proteases as Co-Regulators of Cancer and Apoptosis.

Authors:  Surinder M Soond; Lyudmila V Savvateeva; Vladimir A Makarov; Neonila V Gorokhovets; Paul A Townsend; Andrey A Zamyatnin
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

Review 6.  Update on inflammatory breast cancer.

Authors:  Florence Lerebours; Ivan Bieche; Rosette Lidereau
Journal:  Breast Cancer Res       Date:  2005-01-20       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.